Search

Your search keyword '"Pedro Cahn"' showing total 298 results

Search Constraints

Start Over You searched for: Author "Pedro Cahn" Remove constraint Author: "Pedro Cahn"
298 results on '"Pedro Cahn"'

Search Results

1. Unity is strength: creation and future actions for a consortium for HIV cure research in Latin America and the Caribbean ‘Lac-Cura’

2. Oral and anal microbiome from HIV-exposed individuals: role of host-associated factors in taxa composition and metabolic pathways

3. Preference for long-acting injectable for ART and PrEP among people with and without HIV: a cross-sectional study in Argentina

4. Identifying the needs of older people living with HIV (≥ 50 years old) from multiple centres over the world: a descriptive analysis

5. Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin America: burden and risk factors

6. Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.

7. A small cluster randomised clinical trial to improve health outcomes among Argentine patients disengaged from HIV care

8. EFICÁCIA DURADOURA DE DOLUTEGRAVIR MAIS LAMIVUDINA NO TRATAMENTO ANTIRRETROVIRAL DE ADULTOS NAÏVE COM INFECÇÃO PELO HIV-1: RESULTADOS DE 144 SEMANAS DOS ESTUDOS GEMINI EM PARTICIPANTES DE CENTROS LATINO-AMERICANOS

9. Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8+ T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cART

11. RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

13. Home-based HIV testing: Using different strategies among transgender women in Argentina.

14. Physician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trial

15. Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America

16. Women of Reproductive Age Living with HIV in Argentina: Unique Challenges for Reengagement in Care

17. Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.

18. Monitoring of HIV treatment in seven countries in the WHO Region of the Americas

19. A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy.

20. Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.

21. Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppression

22. Health outcomes among HIV‐positive Latinos initiating antiretroviral therapy in North America versus Central and South America

23. A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA‐ACCORD and CCASAnet clinical cohorts

24. Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.

25. Candidiasis esofágica: análisis clínico y micológico

26. Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression.

27. Host genetic factors associated with symptomatic primary HIV infection and disease progression among Argentinean seroconverters.

28. Use of third line antiretroviral therapy in Latin America.

29. Estimation of HIV-testing rates to maximize early diagnosis-derived benefits at the individual and population level.

30. Routine HIV testing among hospitalized patients in Argentina. is it time for a policy change?

31. VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

32. Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification.

33. Dynamics of adrenal steroids are related to variations in Th1 and Treg populations during Mycobacterium tuberculosis infection in HIV positive persons.

34. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.

35. Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters.

36. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.

37. Correction: HLA-Driven Convergence of HIV-1 Viral Subtypes B and F Toward the Adaptation to Immune Responses in Human Populations.

38. HLA-driven convergence of HIV-1 viral subtypes B and F toward the adaptation to immune responses in human populations.

39. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

40. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

41. The HIV care cascade in Buenos Aires, Argentina: results in a tertiary referral hospital

42. Actualizaciones en Sida e Infectología y el compromiso de seguir creciendo

43. 'If I’m at home, I do it at home': Qualitative study on HIV self-testing among transgender women in Argentina

45. Mpox in persons with advanced HIV infection: a global case series

46. Oral and anal microbiome from HIV-exposed individuals: role of host-associated factors in taxa composition and metabolic pathways

47. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection

48. Nuevas estrategias de TARV: ¿hacia dónde vamos?

49. HIV and aging, biological mechanisms, and therapies: What do we know?

50. Dual therapy with Atazanavir/ritonavir plus Raltegravir versus triple therapy with Atazanavir/ritonavir plus Tenofovir-Emtricitabine after failure to an NNRTI regimen: 48-week results of the randomized pilot study ARTE trial

Catalog

Books, media, physical & digital resources